1,494
Views
0
CrossRef citations to date
0
Altmetric
Emerging and Re-Emerging Coronaviruses

Effectiveness of a broad-spectrum bivalent mRNA vaccine against SARS-CoV-2 variants in preclinical studies

, , , , , , , , , , , , , , , , , , , & ORCID Icon show all
Article: 2321994 | Received 07 Nov 2023, Accepted 16 Feb 2024, Published online: 29 Feb 2024

References

  • Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. N Engl J Med. 2020;383(27):2603–2615. doi:10.1056/NEJMoa2034577
  • Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384(5):403–416. doi:10.1056/NEJMoa2035389
  • Faria NR, Mellan TA, Whittaker C, et al. Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus, Brazil. Science. 2021;372(6544):815–821.
  • Planas D, Veyer D, Baidaliuk A, et al. Reduced sensitivity of SARS-CoV-2 variant delta to antibody neutralization. Nature. 2021;596(7871):276–280. doi:10.1038/s41586-021-03777-9
  • Tegally H, Wilkinson E, Giovanetti M, et al. Detection of a SARS-CoV-2 variant of concern in South Africa. Nature. 2021;592(7854):438–443. doi:10.1038/s41586-021-03402-9
  • Volz E, Mishra S, Chand M, et al. Assessing transmissibility of SARS-CoV-2 lineage B.1.1.7 in England. Nature. 2021;593(7858):266–269. doi:10.1038/s41586-021-03470-x
  • Collie S, Champion J, Moultrie H, et al. Effectiveness of BNT162b2 vaccine against Omicron variant in South Africa. N Engl J Med. 2022;386(5):494–496. doi:10.1056/NEJMc2119270
  • Islam MR, Shahriar M, Bhuiyan MA. The latest Omicron BA.4 and BA.5 lineages are frowning toward COVID-19 preventive measures: A threat to global public health. Health Sci Rep. 2022;5(6):e884. doi:10.1002/hsr2.884
  • Lu L, Mok BWY, Chen LL, et al. Neutralization of severe acute respiratory syndrome coronavirus 2 omicron variant by sera from BNT162b2 or CoronaVac vaccine recipients. Clin Infect Dis. 2022;75(1):e822–e826. doi:10.1093/cid/ciab1041
  • Cele S, Jackson L, Khoury DS, et al. Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization. Nature. 2022;602(7898):654–656. doi:10.1038/s41586-021-04387-1
  • Dejnirattisai W, Huo J, Zhou D, et al. SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses. Cell. 2022;185(3):467–484.e15. doi:10.1016/j.cell.2021.12.046
  • Liu L, Iketani S, Guo Y, et al. Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2. Nature. 2022;602(7898):676–681. doi:10.1038/s41586-021-04388-0
  • Wang Q, Bowen A, Valdez R, et al. Antibody response to omicron BA.4-BA.5 bivalent booster. N Engl J Med. 2023;388(6):567–569. doi:10.1056/NEJMc2213907
  • Collier AY, Miller J, Hachmann NP, et al. Immunogenicity of BA.5 bivalent mRNA vaccine boosters. N Engl J Med. 2023;388(6):565–567. doi:10.1056/NEJMc2213948
  • Lu J, Lu G, Tan S, et al. A COVID-19 mRNA vaccine encoding SARS-CoV-2 virus-like particles induces a strong antiviral-like immune response in mice. Cell Res. 2020;30(10):936–939. doi:10.1038/s41422-020-00392-7
  • Tan S, Hu X, Li Y, et al. Preclinical evaluation of RQ3013, a broad-spectrum mRNA vaccine against SARS-CoV-2 variants. Sci Bull (Beijing). 2023;68(2):3192–3206. doi:10.1016/j.scib.2023.11.024
  • Walsh EE, Frenck RW, Falsey J, et al. Safety and immunogenicity of Two RNA-based COVID-19 vaccine candidates. N Engl J Med. 2020;383(25):2439–2450. doi:10.1056/NEJMoa2027906
  • Corbett KS, Edwards DK, Leist SR, et al. SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness. Nature. 2020;586(7830):567–571. doi:10.1038/s41586-020-2622-0
  • Ebenig A, Muraleedharan S, Kazmierski J, et al. Vaccine-associated enhanced respiratory pathology in COVID-19 hamsters after TH2-biased immunization. Cell Rep. 2022;40(7):111214. doi:10.1016/j.celrep.2022.111214
  • McCray PB Jr., Pewe L, Wohlford-Lenane C, et al. Lethal infection of K18-hACE2 mice infected with severe acute respiratory syndrome coronavirus. J Virol. 2007;81(2):813–821. doi:10.1128/JVI.02012-06
  • Radvak P, Kwon HJ, Kosikova M, et al. SARS-CoV-2 B.1.1.7 (alpha) and B.1.351 (beta) variants induce pathogenic patterns in K18-hACE2 transgenic mice distinct from early strains. Nat Commun. 2021;12(1):6559. doi:10.1038/s41467-021-26803-w
  • Winkler ES, Bailey AL, Kafai NM, et al. SARS-CoV-2 infection of human ACE2-transgenic mice causes severe lung inflammation and impaired function. Nat Immunol. 2020;21(11):1327–1335. doi:10.1038/s41590-020-0778-2
  • Munoz-Fontela C, Dowling WE, Funnell SGP, et al. Animal models for COVID-19. Nature. 2020;586(7830):509–515. doi:10.1038/s41586-020-2787-6
  • Cavagnaro JA. Preclinical safety evaluation of biotechnology-derived pharmaceuticals. Nat Rev Drug Discov. 2002;1(6):469–475. doi:10.1038/nrd822
  • Thompson MG, Burgess JL, Naleway AL, et al. Prevention and attenuation of COVID-19 with the BNT162b2 and mRNA-1273 Vaccines. N Engl J Med. 2021;385(4):320–329. doi:10.1056/NEJMoa2107058
  • Markov PV, Ghafari M, Beer M, et al. The evolution of SARS-CoV-2. Nat Rev Microbiol. 2023;21(6):361–379. doi:10.1038/s41579-023-00878-2
  • Zhao Y, Ni W, Liang S, et al. Vaccination with Span, an antigen guided by SARS-CoV-2 S protein evolution, protects against challenge with viral variants in mice. Sci Transl Med. 2023;15(677):eabo3332. doi:10.1126/scitranslmed.abo3332
  • Offit PA. Bivalent COVID-19 vaccines — A cautionary tale. N Engl J Med. 2023;388(6):481–483. doi:10.1056/NEJMp2215780
  • Cai J, Deng X, Yang J, et al. Modeling transmission of SARS-CoV-2 Omicron in China. Nat Med. 2022;28(7):1468–1475. doi:10.1038/s41591-022-01855-7
  • McBride DS, Garushyants SK, Franks J, et al. Accelerated evolution of SARS-CoV-2 in free-ranging white-tailed deer. Nat Commun. 2023;14(1):5105. doi:10.1038/s41467-023-40706-y